Search Results (7)
 More Search Options
Click the Why column to see why an item matched the search.

MatchTypeWhy
Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.Academic Article Why?
Preclinical efficacy of MEK inhibition in Nras-mutant AML.Academic Article Why?
Protein kinase Cd is a therapeutic target in malignant melanoma with NRAS mutation.Academic Article Why?
Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.Academic Article Why?
Yang, ShiPerson Why?
Chen, ShuyangPerson Why?
Huang, TanniePerson Why?
First Prev Page of 1 Next Last Per Page 
Highlights
Search Criteria
  • NRAS
Filter by Type